ID   BT 333
AC   CVCL_WW61
SY   BT333
DR   cancercelllines; CVCL_WW61
DR   PharmacoDB; BT333_137_2019
DR   Wikidata; Q93432630
RX   PubMed=27723727;
CC   Characteristics: Low-passage-number culture.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val173Met (c.517G>A); ClinVar=VCV000233951; Zygosity=Unspecified (PubMed=27723727).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 19-12-24; Version: 9
//
RX   PubMed=27723727; DOI=10.1038/nbt.3697; PMCID=PMC5142231;
RA   Stevens M.M., Maire C.L., Chou N., Murakami M.A., Knoff D.S.,
RA   Kikuchi Y., Kimmerling R.J., Liu H.-Y., Haidar S., Calistri N.L.,
RA   Cermak N., Olcum S., Cordero N.A., Idbaih A., Wen P.Y.-C.,
RA   Weinstock D.M., Ligon K.L., Manalis S.R.;
RT   "Drug sensitivity of single cancer cells is predicted by changes in
RT   mass accumulation rate.";
RL   Nat. Biotechnol. 34:1161-1167(2016).
//